Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World 'POWERFUL' Study
| Autor: | Eurydiki Michalis, Magdalini Dadakaridou, Argiris Symeonidis, Theodora Assimakopoulou, Vasiliki Pappa, Gerassimos A. Pangalis, Anastasia Pouli, Christos Georgopoulos, Chrysavgi Lalayanni, Panagiotis Repousis, Christos Poziopoulos, Evangelos Terpos, Panagiotis Zikos, Marie-Christine Kyrtsonis, Ioannis Ntanasis-Stathopoulos, Georgios Vassilopoulos, Maria Gavriatopoulou, Kiki Karvounis-Marolachakis, Helen A. Papadaki, Eirini Katodritou, Emmanouil Spanoudakis, Evdoxia Hatjiharissi |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
animal structures ORR lenalidomide lcsh:Medicine pomalidomide Neutropenia Article PFS 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Prospective cohort study Adverse effect duration of response Multiple myeloma Lenalidomide Bortezomib business.industry lcsh:R General Medicine medicine.disease Pomalidomide multiple myeloma refractory 030220 oncology & carcinogenesis Concomitant sense organs business 030215 immunology medicine.drug |
| Zdroj: | Journal of Clinical Medicine, Vol 10, Iss 1509, p 1509 (2021) Journal of Clinical Medicine Volume 10 Issue 7 |
| ISSN: | 2077-0383 |
| Popis: | The “POWERFUL” multicenter, retrospective, and prospective study investigated the effectiveness of pomalidomide plus low-dose dexamethasone (POM/LoDex) therapy in relapsed/refractory multiple myeloma in routine care in Greece. Ninety-nine eligible adult patients treated with POM/LoDex according to the approved label after having received ≥2 prior therapies, including lenalidomide and bortezomib, were consecutively enrolled between 16 November 2017 and 21 February 2019 in 18 hematology departments. Fifty patients (50.5%) started POM/LoDex as third-line treatment. During the treatment period (median: 8.3 months range: 0.3–47.6 months), the median POM dose was 4 mg/day, and 31.3% of the patients received additional antimyeloma agents. The overall response rate was 32.3%. During a median follow-up period of 13.8 months (Kaplan–Meier estimate), the median progression-free survival (PFS) was 10.5 months (95% CI: 7.4–14.4). The PFS was not significantly different between patients receiving POM/LoDex in the third versus later line of therapy, nor between patients receiving concomitant antimyeloma therapy versus POM/LoDEx doublet. During the prospective safety data collection period (median: 7.6 months) among patients with prospective follow-up (N = 75), POM-related adverse event incidence rate was 42.7% (serious: 18.7% grade ≥ 3 hematological POM-related adverse events: 8.0%). Only neutropenia (13.3%) was reported at a frequency ≥10%. In conclusion, in this real-world study, POM/LoDex displayed a long PFS with no new safety signals emerging. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|